Drugs / HKT288
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02947152 | Dec 2016 → Sep 2017 | malignant epithelial tumor of ovary, renal cell carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HKT288 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02947152 ↗ |
| Route | Intravenous | “for intravenous administration” NCT02947152 ↗ |
| Target | CDH6 | “Cadherin-6-targeting antibody-drug conjugate” NCT02947152 ↗ |